Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has received an average recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $12.33.
PIRS has been the topic of a number of recent analyst reports. HC Wainwright set a $12.00 target price on Pieris Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, September 4th. BidaskClub upgraded Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 16th.
Pieris Pharmaceuticals stock traded down $0.12 during midday trading on Tuesday, reaching $4.71. The company’s stock had a trading volume of 1,834 shares, compared to its average volume of 369,385. Pieris Pharmaceuticals has a 52 week low of $4.43 and a 52 week high of $9.75. The stock has a market cap of $280.98 million, a PE ratio of -11.78 and a beta of 1.62.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Thursday, August 9th. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.01 by ($0.01). Pieris Pharmaceuticals had a negative net margin of 22.38% and a negative return on equity of 27.81%. The business had revenue of $11.69 million during the quarter, compared to the consensus estimate of $13.46 million. Research analysts forecast that Pieris Pharmaceuticals will post -0.49 earnings per share for the current year.
In other Pieris Pharmaceuticals news, Director Christopher P. Kiritsy bought 5,000 shares of the firm’s stock in a transaction on Friday, September 14th. The shares were purchased at an average price of $5.11 per share, for a total transaction of $25,550.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $51,100. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 5.07% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Pieris Pharmaceuticals by 49.1% during the second quarter. BlackRock Inc. now owns 2,685,490 shares of the biotechnology company’s stock worth $13,616,000 after purchasing an additional 884,348 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Pieris Pharmaceuticals by 45.5% during the second quarter. Acadian Asset Management LLC now owns 2,124,873 shares of the biotechnology company’s stock worth $10,773,000 after purchasing an additional 664,032 shares during the last quarter. Aquilo Capital Management LLC bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth about $10,013,000. Millennium Management LLC grew its holdings in shares of Pieris Pharmaceuticals by 160.7% during the first quarter. Millennium Management LLC now owns 1,824,109 shares of the biotechnology company’s stock worth $12,440,000 after purchasing an additional 1,124,338 shares during the last quarter. Finally, Prosight Management LP grew its holdings in shares of Pieris Pharmaceuticals by 141.2% during the second quarter. Prosight Management LP now owns 1,360,000 shares of the biotechnology company’s stock worth $6,895,000 after purchasing an additional 796,237 shares during the last quarter. Institutional investors own 64.89% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Story: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.